ZyVersa Therapeutics (NASDAQ:ZVSA) stock is sliding lower on Wednesday following a couple of announcements from the company.
The first is the company’s publication of an article in the peer-reviewed Journal of Neuroinflammation. This article covers the “potential of ASC specks as a therapeutic target for Parkinson’s disease.” Unfortunately for ZVSA stock, investors don’t seem impressed by the news.
The second thing worth noting is ZyVersa preparing for its Planet Microcap Showcase later today. That event is scheduled to take place at 5:00 p.m. Eastern today. Since that is after market close, traders won’t see the full effect of this news until tomorrow.
What Else to Know About ZVSA Stock
In addition to this news, shares of ZVSA stock are seeing heavy trading on Wednesday. As of this writing, more than 972,000 shares have changed hands. That’s already above the stock’s daily average trading volume of about 386,000 units as investors sell shares.
ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company. It is focused on the development of drugs to treat patients suffering from renal and inflammatory diseases with unmet medical needs.
The company was founded in 2021 and operates out of Weston, Florida. It went public late last year through a special purpose acquisition company (SPAC) merger with Larkspur Health Acquisition.
ZVSA stock is down 46% during pre-market trading on Wednesday.
There’s even more stock market news traders need to know about below!
We’ve got all of the hottest stock market coverage investors need to know about on Wednesday! A few examples include why shares of IN8bio (NASDAQ:INAB) and Clearmind Medicine (NASDAQ:CMND) stock are up, as well as the biggest pre-market stock movers on Wednesday morning. You can catch up on all of this at the following links!
More Wednesday Stock Market News
- Why Is IN8bio (INAB) Stock Up 9% Today?
- Why Is Clearmind Medicine (CMND) Stock Up 45% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.